Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

723
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
723
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

113
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
113
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

1.8K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.8K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

456
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
456
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

3.2K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early postnatal eosinophil expansion associates with gut microbial-metabolic features and type 2 immunity in preterm infants.

Mucosal immunology·2026
Same author

Folate as a Key Regulator of Animal Intestinal Homeostasis: From Metabolism to Microbiota and Barrier Function.

Animals : an open access journal from MDPI·2026
Same author

Association between hepatic vein Doppler and echocardiographic diastolic indices with invasively measured right ventricular filling pressures in pediatric pulmonary arterial hypertension.

International journal of cardiology·2026
Same author

Van der Waals strain hardening and large uniform tensile elongation in GaSe.

Nature materials·2026
Same author

Neonatal intensive care unit exposures reprogram microbiome-metabolome trajectories and modulate host calprotectin in preterm infants: a longitudinal multi-omics study.

NPJ biofilms and microbiomes·2026
Same author

Synthetic control over proximity of metal and acid dual sites switches the selectivity of acetophenone hydrodeoxygenation.

Proceedings of the National Academy of Sciences of the United States of America·2026

Related Experiment Video

Updated: Mar 13, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K

Treatment of Hepatitis E.

Wei Hui1, Linlin Wei2, Zhuo Li3

  • 1Department of Liver Diseases Endocrine, Youan Hospital, Capital Medical University, No. 8 XitoutiaoYouanmenWai, Fengtai District, Beijing, 100069, China. huiwei7701@sina.cn.

Advances in Experimental Medicine and Biology
|October 15, 2016
PubMed
Summary

Hepatitis E virus (HEV) infections can be acute or chronic. Ribavirin is recommended for chronic HEV, particularly in transplant patients, while supportive care is crucial for acute cases and liver failure.

Keywords:
Acute hepatitis EChronic hepatitis EHEV-related liver failurePegylated interferonRibavirinTreatment

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

7.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis E virus (HEV) is a leading cause of viral hepatitis globally.
  • While often self-limiting, HEV can lead to chronic infection and severe complications like cholestasis and liver failure.

Purpose of the Study:

  • To review current therapeutic strategies for Hepatitis E virus infections.
  • To highlight the role of ribavirin and supportive care in managing HEV.

Main Methods:

  • Literature review of HEV treatment modalities.
  • Analysis of therapeutic outcomes for acute and chronic HEV.
  • Evaluation of management for HEV-associated complications.

Main Results:

  • No specific therapy exists for acute HEV; supportive care is standard.
  • Ribavirin is advised as first-line treatment for chronic HEV, especially in solid organ transplant recipients.
  • Pegylated interferon-α has shown efficacy but carries significant side effects.

Conclusions:

  • Current HEV therapy focuses on symptom management and supportive care.
  • Ribavirin has demonstrated success in preventing liver transplantation in HEV patients.
  • Liver transplantation remains the definitive treatment for acute-on-chronic liver failure unresponsive to other measures.